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Abstract
Pompe disease is an inherited disorder caused by disease‐associated variants in the
acid α‐glucosidase gene (GAA). The Pompe disease GAA variant database (http://
www.pompevariantdatabase.nl) is a curated, open‐source, disease‐specific database,
and lists disease‐associated GAA variants, in silico predictions, and clinical pheno-
types reported until 2016. Here, we provide an update to include 226 disease‐
associated variants that were published until 2020. We also listed 148 common GAA
sequence variants that do not cause Pompe disease. GAA variants with unknown
severity that were identified only in newborn screening programs were listed as a
new feature to indicate the reason why phenotypes were still unknown. Expression
studies were performed for common missense variants to predict their severity. The
updated Pompe disease GAA variant database now includes 648 disease‐associated
variants, 26 variants from newborn screening, and 237 variants with unknown se-
verity. Regular updates of the Pompe disease GAA variant database will be required
to improve genetic counseling and the study of genotype–phenotype relationships.
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1 | INTRODUCTION
Pompe disease (glycogen storage disease type II; MIM #232300) is
an autosomal recessive disorder caused by disease‐associated var-
iants in the acid α‐glucosidase (GAA) gene, resulting in a deficiency of
the GAA enzyme, accumulation of lysosomal glycogen, and
progressive muscle weakness. The clinical spectrum of Pompe dis-
ease is broad (Güngör & Reuser, 2013). The most severe classic in-
fantile phenotype presents shortly after birth with hypertrophic
cardiomyopathy and generalized muscle weakness. These patients
die in the first year of life due to cardiorespiratory insufficiency if left
untreated. The slower progressing phenotype is characterized by
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muscle weakness that can appear at any age from <1 year into
adulthood. These patients are generally spared from cardiac symp-
toms (Kohler et al., 2018; van der Ploeg & Reuser, 2008). Enzyme
replacement therapy (ERT) with intravenously applied recombinant
human GAA is available since 2006. ERT normalizes hypertrophic
cardiomyopathy, improves motor function, and extends survival.
The differences between phenotypes in Pompe disease can, in
part, be attributed to the severity of the disease‐associated variants
present in the GAA gene. Classic infantile patients carry two disease‐
associated variants that completely disrupt the function of GAA (i.e.,
null alleles). This group of patients can be subdivided based on their
cross‐reactive immunological material (CRIM) status, which is de-
fined by the disease‐associated variants involved. When two GAA
variants are present that do not result in GAA protein expression,
the patient is classified as CRIM‐negative. When at least one GAA
variant gives rise to GAA protein expression (in which the GAA
protein can be enzymatically inactive), the patient is classified as
CRIM‐positive. The clinical importance of CRIM status is highlighted
by the fact that CRIM‐negative classic infantile patients have a
poorer prognosis compared with CRIM‐positive classic infantile pa-
tients, possibly due to the formation of high sustained anti‐GAA
antibody titers upon treatment with ERT (Bali et al., 2012; van
Gelder et al., 2015). Patients who do not have the classic infantile
phenotype carry at least one disease‐associated variant that allows
some residual enzymatic activity. These patients are, by definition,
CRIM‐positive (Kroos et al., 2012b; Kulessa et al., 2020).
The “Pompe disease GAA variant database” (http://www.
pompevariantdatabase.nl) is an open‐access database that lists and
classifies all reported variants in the GAA gene. We recently revised this
database to include clinical data from patients collected from the lit-
erature, adapted the classification system for variant severity, and ad-
ded (predicted) CRIM status for disease‐associated variants. The
database included literature up to May 2016, resulting in a total of 561
variants (Niño et al., 2019). In recent years, many new patients and GAA
variants have been reported. These include findings from large patient
populations, such as the French nationwide study (246 patients with
late‐onset Pompe disease) and the Pompe registry (1079 patients from
26 countries; Reuser et al., 2019; Semplicini et al., 2018).
In addition, various countries, including Taiwan, the United
States, Italy, Brazil, and Japan, have implemented newborn screening
(NBS) programs for Pompe disease, resulting in an increase of var-
iants of unknown significance (VUS; Bravo et al., 2017; Burlina
et al., 2018; Chien et al., 2019; Elliott et al., 2016; Momosaki
et al., 2019; Yang et al., 2014). For variants associated with late
onset, the associated phenotypes from NBS cases are still unknown
as symptom onset could, in principle, be delayed until (late) adult-
hood. It will be important to monitor the onset and progress of
symptoms in patients identified via NBS programs closely to de-
termine the severity of the newly identified genetic variants.
Public databases, such as dbSNP (https://www.ncbi.nlm.nih.gov/
snp) and gnomAD (https://gnomad.broadinstitute.org), provide a
source of variants that have been detected in various genome‐wide
studies (Karczewski et al., 2020; Sherry et al., 2001). A large
percentage of these variants represent common sequence variants
that have a minor allele frequency (MAF) ≥ 1%. Several of these
variants have already been reported for the GAA gene and have been
ruled out to cause Pompe disease (Kroos et al., 2007; Labrousse
et al., 2010; Turaça et al., 2015). However, most of the common
sequence variants in these databases are listed as VUSs and may lead
to misinterpretation during molecular diagnostics.
In this study, we provide an update of the Pompe disease GAA
variant database with variants and patients described in the lit-
erature up to January 2020. We included information on novel
GAA variants that were identified via NBS and for which no phe-
notype was yet known. Known common sequence variants in the
GAA gene that do not cause Pompe disease have now also been
added to prevent misdiagnosis. In addition, selected common
missense variants were tested in expression studies and also this
information was added to the updated database. The database
provides a curated up‐to‐date reference source for the molecular
diagnosis of Pompe disease.
2 | METHODS
The Pompe disease GAA variant database is publicly available at
http://www.pompevariantdatabase.nl. The previous version of
the database included literature until 2016; the update described
here contains variants from publications up to January 2020.
Additionally, NBS studies that screened for Pompe disease were
now included if the authors provided the genotypes of the de-
scribed cases. Novel variants were analyzed as described in Niño
et al. (2019). Variants were annotated based on the reference
sequences NM_000152.3 for GAA messenger RNA (mRNA),
LRG_673 genomic sequence for describing variants in intronic
sequences, and NP_000143.2 for GAA protein. Exon annotations
were based on the human genomic build (GRCH37/hg19) for
exons 2–20; however, changes were made to the annotation of
exon 1 to reflect the findings of (GRCH38/hg38). Within this
region, a new 195‐bp intron was identified at positions c.−112
and c.−113. Therefore, the region that was previously annotated
as exon 1 has been split between exons 1A and 1B, which are
separated by intron 1A. Intron 1 has been renamed to intron 1B.
This numbering was made to maintain the same numbering of
subsequent exons compared with existing literature.
Common sequence variants in the GAA gene (hg38
Chr17:80,101,556‐80,119,881) were extracted from gnomAD and
were categorized as “not disease‐associated.” Combined Annotation‐
Dependent Depletion (CADD) in silico predictions were performed
using the CADD (https://cadd.gs.washington.edu) platform, which
compiles different tools for analysis of intronic insertion and deletion
variants (Rentzsch et al., 2019). The MAF and CADD scores were ob-
tained in April 2020. Predictions of effect on pre‐mRNA splicing were
performed using Alamut Visual v.2.15 (Interactive Biosoftware).
Functional studies were performed using site‐directed muta-
genesis (SDM) to generate complementary DNA (cDNA) expression
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TABLE 1 Novel disease‐associated variants added to the Pompe variant database
DNA nomenclature Phenotype combined with a null allele DNA nomenclature Phenotype combined with a null allele
Ch37/hg19 chr17:78,059,821_
78,076,592del
Unknown (disease‐associated) c.1057C>T Unknown (disease‐associated)
c.−113+2T>A Unknown (disease‐associated) c.1057del Unknown (disease‐associated)
c.−32‐17_−32‐10delins(30) Classic infantile c.1099T>G Unknown (disease‐associated)
c.−32‐1G>C Unknown (disease‐associated) c.1106T>A Unknown (disease‐associated)
c.40_47del Classic infantile c.1109G>A Unknown (disease‐associated)
c.104T>C Classic infantile c.1114C>G Unknown (disease‐associated)
c.169C>T Classic infantile c.1114C>T Unknown (disease‐associated)
c.205C>T Unknown (disease‐associated) c.1121G>A Unknown (disease‐associated)
c.258C>A Unknown (disease‐associated) c.1127_1130del Unknown (disease‐associated)
c.265C>T Unknown (disease‐associated) c.1129G>A Unknown (disease‐associated)
c.295_314del Unknown (disease‐associated) c.1153del Unknown (disease‐associated)
c.323G>C Unknown (disease‐associated) c.1192del Unknown (disease‐associated)
c.365del Unknown (disease‐associated) c.1193del Unknown (disease‐associated)
c.380G>A Unknown (disease‐associated) c.1201C>A Unknown (disease‐associated)
c.397T>G Unknown (disease‐associated) c.1209C>A Unknown (disease‐associated)
c.437del Classic infantile c.1211A>C Unknown (disease‐associated)
c.445A>C Unknown (disease‐associated) c.1211A>T Classic infantile
c.484A>C Classic infantile c.1212C>G Unknown (disease‐associated)
c.502C>T Unknown (disease‐associated) c.1216G>A Childhood
c.505C>A Unknown (disease‐associated) c.1219T>C Unknown (disease‐associated)
c.517_519del Childhood c.1221C>A Classic infantile
c.541_545del Classic infantile c.1221del Unknown (disease‐associated)
c.547‐1G>C Unknown (disease‐associated) c.1226_1227insG Classic infantile
c.568C>T Unknown (disease‐associated) c.1231del Unknown (disease‐associated)
c.665T>G Classic infantile c.1240T>C Unknown (disease‐associated)
c.686G>C Unknown (disease‐associated) c.1241del Classic infantile
c.691C>T Unknown (disease‐associated) c.1242C>A Unknown (disease‐associated)
c.692T>C Unknown (disease‐associated) c.1249A>C Unknown (disease‐associated)
c.692+1G>T Unknown (disease‐associated) c.1281G>T Classic infantile
c.693‐2A>C Classic infantile c.1292_1295dup Classic infantile
c.693‐1G>C Unknown (disease‐associated) c.1293_1326+57del Unknown (disease‐associated)
c.715_716del Unknown (disease‐associated) c.1298A>C Classic infantile
c.730C>T Classic infantile c.1311_1312ins(26) Classic infantile
c.736del Unknown (disease‐associated) c.1320_1322del Classic infantile
c.756_757insT Unknown (disease‐associated) c.1327‐54_1437+178del Classic infantile
c.759del Unknown (disease‐associated) c.1358_1361del Classic infantile
c.766_784del Unknown (disease‐associated) c.1378G>T Unknown (disease‐associated)
c.781G>A Classic infantile c.1388_1406del Unknown (disease‐associated)
c.784G>C Unknown (disease‐associated) c.1396dup Unknown (disease‐associated)
(Continues)
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TABLE 1 (Continued)
DNA nomenclature Phenotype combined with a null allele DNA nomenclature Phenotype combined with a null allele
c.796C>A Childhood c.1402A>T Unknown (disease‐associated)
c.799_803delinsA Unknown (disease‐associated) c.1409A>G Unknown (disease‐associated)
c.837G>C Unknown (disease‐associated) c.1431del Classic infantile
c.841C>T Unknown (disease‐associated) c.1441del Unknown (disease‐associated)
c.876C>G Classic infantile c.1447G>T Unknown (disease‐associated)
c.878G>T Unknown (disease‐associated) c.1456G>T Unknown (disease‐associated)
c.883C>A Unknown (disease‐associated) c.1464dup Classic infantile
c.930_932del Classic infantile c.1470C>A Childhood
c.942C>A Unknown (disease‐associated) c.1477C>T Unknown (disease‐associated)
c.947A>G Classic infantile c.1493G>A Classic infantile
c.950C>T Unknown (disease‐associated) c.1501_1515del Unknown (disease‐associated)
c.955+1G>A Classic infantile c.1507del Classic infantile
c.971dup Classic infantile c.1526A>T Unknown (disease‐associated)
c.982_988del Classic infantile c.1531C>A Unknown (disease‐associated)
c.983T>C Classic infantile c.1537G>A Unknown (disease‐associated)
c.994_995insTT Unknown (disease‐associated) c.1538A>G Classic infantile
c.1000G>T Classic infantile c.1551+3A>T Unknown (disease‐associated)
c.1004_1005dup Unknown (disease‐associated) c.1551+5G>A Unknown (disease‐associated)
c.1047del Unknown (disease‐associated) c.1559A>G Unknown (disease‐associated)
c.1560C>G Unknown (disease‐associated) c.2096T>C Unknown (disease‐associated)
c.1579_1580del Classic infantile c.2109del Unknown (disease‐associated)
c.1583G>C Unknown (disease‐associated) c.2131A>C Classic infantile
c.1594G>A Adult c.2146G>C Unknown (disease‐associated)
c.1597T>G Classic infantile c.2153_2156delinsACGCCG Classic infantile
c.1602_1605delinsAGG Classic infantile c.2182_2183del Unknown (disease‐associated)
c.1610del Unknown (disease‐associated) c.2190‐345A>G Unknown (disease‐associated)
c.1627T>G Unknown (disease‐associated) c.2205dup Classic infantile
c.1629C>G Unknown (disease‐associated) c.2213G>A Classic infantile
c.1636G>C Unknown (disease‐associated) c.2221G>A Classic infantile
c.1636+5G>A Classic infantile c.2222A>T Unknown (disease‐associated)
c.1650del Unknown (disease‐associated) c.2234T>C Classic infantile
c.1657C>T Classic infantile c.2235dup Classic infantile
c.1681_1699dup Unknown (disease‐associated) c.2237G>T Unknown (disease‐associated)
c.1688A>T Unknown (disease‐associated) c.2240G>A Unknown (disease‐associated)
c.1716C>A Classic infantile c.2261dup Unknown (disease‐associated)
c.1721T>C Unknown (disease‐associated) c.2294G>A Classic infantile
c.1753_2799del Classic infantile c.2296T>A Classic infantile
c.1754+1dup Unknown (disease‐associated) c.2297A>C Classic infantile
c.1754+2T>C Unknown (disease‐associated) c.2304del Unknown (disease‐associated)
c.1780C>T Unknown (disease‐associated) c.2320G>A Unknown (disease‐associated)
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constructs containing the missense variant of interest as described
(in 't Groen et al., 2020). The activity of the GAA protein produced by
the constructs was measured using 4‐methylumbelliferyl‐α‐D‐
glucopyranoside (4‐MU) as a substrate in transfected COS‐7 cells, as
described in Kroos et al. (2008). Statistical analysis was performed
using one‐way analysis of variance with Tukey honestly significant
difference post hoc multiple testing corrections. p < .05 was con-
sidered significant.
TABLE 1 (Continued)
DNA nomenclature Phenotype combined with a null allele DNA nomenclature Phenotype combined with a null allele
c.1784C>T Unknown (disease‐associated) c.2331+5G>C Classic infantile
c.1799G>C Unknown (disease‐associated) c.2331+102del Unknown (disease‐associated)
c.1822del Unknown (disease‐associated) c.2334_2335dup Unknown (disease‐associated)
c.1825T>G Unknown (disease‐associated) c.2377_2378insAC Classic infantile
c.1835A>C Unknown (disease‐associated) c.2380dup Unknown (disease‐associated)
c.1835A>G Unknown (disease‐associated) c.2395C>T Unknown (disease‐associated)
c.1837T>G Unknown (disease‐associated) c.2407C>T Unknown (disease‐associated)
c.1839G>C Unknown (disease‐associated) c.2411G>A Classic infantile
c.1844_1846del Unknown (disease‐associated) c.2459_2461del Unknown (disease‐associated)
c.1844G>T Classic infantile c.2460dup Unknown (disease‐associated)
c.1844G>A Classic infantile c.2474C>G Unknown (disease‐associated)
c.1847dup Unknown (disease‐associated) c.2480A>G Unknown (disease‐associated)
c.1859C>A Unknown (disease‐associated) c.2515C>T Unknown (disease‐associated)
c.1879_1881del Classic infantile c.2537C>A Unknown (disease‐associated)
c.1888+2_1888+15del Classic infantile c.2544del Unknown (disease‐associated)
c.1895T>C Unknown (disease‐associated) c.2563G>C Classic infantile
c.1895T>G Classic infantile c.2578G>A Unknown (disease‐associated)
c.1903A>G Unknown (disease‐associated) c.2584G>A Childhood
c.1913G>A Classic infantile c.2585del Classic infantile
c.1944_1950del Unknown (disease‐associated) c.2596del Unknown (disease‐associated)
c.1952dup Unknown (disease‐associated) c.2619C>G Unknown (disease‐associated)
c.1961C>G Unknown (disease‐associated) c.2636T>C Classic infantile
c.2004C>A Unknown (disease‐associated) c.2655_2656del Unknown (disease‐associated)
c.2015G>T Unknown (disease‐associated) c.2716G>A Unknown (disease‐associated)
c.2020C>G Unknown (disease‐associated) c.2720T>C Unknown (disease‐associated)
c.2020C>T Unknown (disease‐associated) c.2725G>A Unknown (disease‐associated)
c.2024A>G Classic infantile c.2740dup Unknown (disease‐associated)
c.2040+2dup Unknown (disease‐associated) c.2742dup Classic infantile
c.2040+29_2190‐270del Classic infantile c.2757del Unknown (disease‐associated)
c.2041‐2A>G Classic infantile c.2799+5G>A Unknown (disease‐associated)
c.2051C>A Unknown (disease‐associated) c.2800‐1G>C Classic infantile
c.2051C>G Unknown (disease‐associated) c.2843dup Classic infantile
c.2051C>T Classic infantile c.2845_2847del Unknown (disease‐associated)
c.2056_2057delinsCC Unknown (disease‐associated)
c.2084dup Unknown (disease‐associated)
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3 | RESULTS AND DISCUSSION
Table 1 provides an overview of the novel variants. We per-
formed a literature search covering the past 4 years and identi-
fied 80 publications (listed in the updated database and Table S1)
that described 350 novel variants, of which 226 were considered
to be disease‐associated (Table 1 and Figure 1a). Seventy‐six
novel variants (33%) were present in combination with a null
allele, which allowed prediction of the clinical severity of these
variants (Table 1 and Figure 1b). In addition, the inclusion of new
patient information allowed us to classify the severity of
55 variants that were already present in the database. This re-
sulted in a new total of 911 GAA variants, of which 648 were
disease‐associated (71%). In total, 336 out of 648 disease‐
associated variants (52%) could be associated with a clinical
phenotype. The geographical or ethnical distribution of reported
patients remained similar to what was described previously. The
majority of patients had a Caucasian background or were of
Caucasian descent (data not shown). This introduces a bias in the
current version of the database and indicates the necessity of
extending the database to patients of other descent. Mapping of




F IGURE 1 Overview of variants, comparing the previous (Niño et al., 2019) and updated version of the Pompe disease GAA variant database
(http://www.pompevariantdatabase.nl). (a) Number of disease‐associated and unknown variants in the previous database (left) and the updated
version of the database (right). (b) Number of disease‐associated variants classified based on the predicted clinical phenotype when combined
with a null allele in the previous database (left) and in the updated version of the database (right). (c) Distribution of disease‐associated
missense variants listed in the updated database, based on the protein domains of GAA and the predicted clinical phenotype when combined
with a null allele. Numbers are corrected for the length of each domain. †Two entries in the previous version of the database were removed as
the variants were described twice using different nomenclatures. ‡For 36 variants listed in the previous version of the database, a
reclassification of the phenotypic severity was performed due to the addition of novel patients included in this update
124 | de FARIA ET AL.
TABLE 2 List of common sequence variants located within the boundaries of the GAA gene







Exon 1A, 5ʹ UTR c.−338C>G rs144639114 2% No effect on splicing 6.524
Exon 1A, 5ʹ UTR c.−260G>C rs2304849 16% No effect on splicing 8.996
Exon 1A, 5ʹ UTR c.−178G>A rs77514632 2% No effect on splicing 9.948
Exon 1B, 5ʹ UTR c.−75C>G rs80020206 0.9% (3% in African population) No effect on splicing 9.989
Intron 1B c.−33+219G>C rs4889961 75% No effect on splicing 0.866
Intron 1B c.−33+316C>A rs8077055 20% No effect on splicing 9.079
Intron 1B c.−33+317C>T rs8077056 20% No effect on splicing 8.579
Intron 1B c.−33+671A>C rs55751636 31% No effect on splicing 1.456
Intron 1B c.−33+757G>A rs28413147 5% No effect on splicing 4.974
Intron 1B c.−33+903A>C rs12450199 34% No effect on splicing 8.196
Intron 1B c.−33+1104A>G rs11150841 75% No effect on splicing 6.976
Intron 1B c.−33+1172G>A rs1442315 5% No effect on splicing 0.064
Intron 1B c.−33+1190G>T rs12602593 10% No effect on splicing 1.784
Intron 1B c.−33+1309T>C rs1442314 76% No effect on splicing 1.752
Intron 1B c.−32‐1298G>C rs12602610 33% No effect on splicing 2.604
Intron 1B c.−32‐1124C>T rs58959690 20% No effect on splicing 5.825
Intron 1B c.−32‐884T>C rs145362066 0.9% (3% in African population) No effect on splicing 3.993
Intron 1B c.−32‐793C>G rs55666739 2% No effect on splicing 4.041
Intron 1B c.−32‐721G>C rs75754966 2% Generates a new cryptic
splice accepter site
1.008
Intron 1B c.−32‐686A>G rs147264695 0.3% (1% in Finnish population) No effect on splicing 4.349
Intron 1B c.−32‐640C>T rs12600845 51% No effect on splicing 0.136
Intron 1B c.−32‐521G>T rs115060925 1% Generates a new cryptic
splice donor site
0.639
Intron 1B c.−32‐494C>G rs140325572 2% No effect on splicing 0.036
Intron 1B c.−32‐462G>A rs74003606 5% No effect on splicing 0.226
Exon 2 c.271G>A rs1800299 2% No effect on splicing 0.256
Exon 2 c.324T>C rs1800300 72% No effect on splicing 8.391
Exon 2 c.447G>A rs2289536 0.5% (3% in East Asian
population)
No effect on splicing 1.252
Intron 2 c.546+293G>A rs34746710 20% No effect on splicing 1.899
Intron 2 c.547‐243C>G rs8065426 67% No effect on splicing 2.529
Intron 2 c.547‐238T>C rs12452263 20% No effect on splicing 5.667
Intron 2 c.547‐67C>G rs8069491 67% No effect on splicing 1.337
Intron 2 c.547‐39T>G rs12452721 67% Loss of cryptic splice
donor site
2.78
Intron 2 c.547‐4C>G rs3816256 67% No effect on splicing 4.721
Exon 3 c.596A>G rs1042393 67% No effect on splicing 0.548
Exon 3 c.642C>T rs1800301 18% No effect on splicing 1.805
Exon 3 c.668G>A rs1042395 67% No effect on splicing 1.46
Intron 3 c.692+38C>T rs2304848 3% 5.574
(Continues)
de FARIA ET AL. | 125
TABLE 2 (Continued)







Generates a new cryptic
splice donor site
Intron 3 c.692+144A>G rs2304847 67% No effect on splicing 3.653
Intron 3 c.692+509T>C rs8082405 66% No effect on splicing 3.271
Intron 3 c.692+674G>C rs8078350 67% No effect on splicing 4.501
Intron 3 c.692+751T>C rs8068051 67% No effect on splicing 2.363
Intron 3 c.693‐586G>A rs112308142 3% No effect on splicing 2.71
Intron 3 c.693‐585T>C rs8068555 67% No effect on splicing 4.133
Intron 3 c.693‐559C>T rs12602422 67% No effect on splicing 1.879
Intron 3 c.693‐491G>A rs12948631 67% No effect on splicing 3.629
Intron 3 c.693‐441C>G rs12602440 67% Loss of a cryptic splice
acceptor site
7.559
Intron 3 c.693‐434C>A rs12941269 66% No effect on splicing 4.416
Intron 3 c.693‐414C>G rs12941289 66% Loss of a cryptic splice
acceptor site
0.077
Intron 3 c.693‐413A>G rs12937590 67% Loss of a cryptic splice
acceptor site
1.544
Intron 3 c.693‐216T>A rs11150844 67% No effect on splicing 4.13
Intron 3 c.693‐94C>T rs79849256 0.2% (3% in East Asian
population)
No effect on splicing 9.666
Intron 3 c.693‐78C>T rs74003611 6% No effect on splicing 0.06
Intron 3 c.693‐49C>T rs78855075 7% No effect on splicing 2.374
Exon 4 c.852G>A rs142626724 0.6% (1% in European
population)
No effect on splicing 1.095
Intron 4 c.858+30T>C rs2304845 66% No effect on splicing 0.067
Exon 5 c.921A>T rs1800303 8% No effect on splicing 9.101
Intron 5 c.955+12G>A rs2252455 69% No effect on splicing 0.981
Intron 5 c.955+155C>A rs9901190 5% No effect on splicing 7.196
Intron 5 c.955+167C>T rs77717164 0.7% (6% in East Asian
population)
No effect on splicing 6.348
Intron 5 c.956‐107G>A rs2241888 73% No effect on splicing 5.835
Intron 5 c.956‐84C>T rs2241887 67% No effect on splicing 0.061
Intron 6 c.1075+13C>T rs41292402 1% No effect on splicing 7.496
Exon 8 c.1203G>A rs1800304 67% No effect on splicing 5.972
Exon 8 c.1286A>G rs200294882 0.07% (1% in East Asian
population)
Loss of cryptic splice acceptor
site and generates a new
cryptic splice donor site
0.068
Intron 8 c.1326+132G>A rs894306 67% No effect on splicing 1.999
Intron 8 c.1326+459C>T rs74679377 0.7% (6% in East Asian
population)
No effect on splicing 0.435
Intron 8 c.1326+460G>A rs12150323 2% No effect on splicing 0.322
Intron 8 c.1327‐514G>A rs72850826 5% No effect on splicing 1.914
Intron 8 c.1327‐356G>T rs6565640 73% No effect on splicing 0.258
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Intron 8 c.1327‐321del rs140385114 7% No effect on splicing 0.888
Intron 8 c.1327‐269A>G rs6565641 67% No effect on splicing 4.207
Intron 8 c.1327‐209C>T rs76604157 0.3% (6% in East Asian
population)
No effect on splicing 0.471
Intron 8 c.1327‐179G>A rs2278620 20% No effect on splicing 0.643
Intron 8 c.1327‐118A>G rs74003628 7% No effect on splicing 0.184
Intron 8 c.1327‐18A>G rs2278619 72% No effect on splicing 0.124
Exon 9 c.1374C>T rs1800305 7% No effect on splicing 0.206
Intron 9 c.1438‐220A>G rs2278618 67% No effect on splicing 6.607
Intron 9 c.1438‐108G>A rs12944802 67% No effect on splicing 0.013
Intron 9 c.1438‐19G>C rs2304844 67% No effect on splicing 3.529
Intron 10 c.1551+42G>A rs115427918 0.9% (3% in African population) No effect on splicing 5.792
Intron 10 c.1551+49C>A rs2304843 67% No effect on splicing 7.131
Exon 11 c.1581G>A rs1042396 23% No effect on splicing 6.758
Intron 11 c.1636+43G>T rs2304842 5% Generates a new cryptic
splice accepter site
6.859
Intron 11 c.1636+117del rs199788201 59% No effect on splicing 0.045
Intron 11 c.1636+117C>T rs12945868 11% No effect on splicing 0.181
Intron 11 c.1636+118G>T rs4889817 59% No effect on splicing 3.161
Intron 11 c.1636+205C>T rs79673008 3% No effect on splicing 0.013
Intron 11 c.1636+210G>A rs79487884 5% No effect on splicing 1.463
Intron 11 c.1636+269C>T rs111625854 2% No effect on splicing 3.828
Intron 11 c.1636+284G>C rs111551014 2% No effect on splicing 1.81
Intron 11 c.1636+389C>G rs7221675 63% No effect on splicing 0.573
Intron 11 c.1636+390A>G rs7209921 63% No effect on splicing 1.829
Intron 11 c.1636+404A>G rs4889818 74% No effect on splicing 1.902
Intron 11 c.1637‐185A>G rs12951255 55% No effect on splicing 0.576
Exon 12 c.1726G>A rs1800307 2% Generates a new cryptic
splice acceptor
0.268
Intron 12 c.1754+12G>A rs2304840 6% No effect on splicing 4.325
Intron 12 c.1754+100C>T rs113688685 0.9% (3% in African population) No effect on splicing 8.142
Intron 12 c.1754+104C>G rs2304839 5% No effect on splicing 0.763
Intron 12 c.1754+144C>T rs2304838 61% No effect on splicing 1.787
Intron 12 c.1755‐186A>G rs62075593 2% No effect on splicing 2.032
Intron 13 c.1888+21G>A rs2304837 6% No effect on splicing 3.378
Intron 14 c.2040+20A>G rs2304836 72% No effect on splicing 2.163
Intron 14 c.2040+66C>T rs2304835 7% No effect on splicing 3.54
Intron 14 c.2040+69A>G rs2304834 6% No effect on splicing 0.027
Intron 14 c.2041‐64G>A rs2304833 27% No effect on splicing 0.371
Exon 15 c.2065G>A rs1800309 6% No effect on splicing 1.783
(Continues)
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Exon 15 c.2133A>G rs1800310 27% No effect on splicing 1.134
Intron 15 c.2189+95C>T rs72850840 5% No effect on splicing 3,771
Intron 15 c.2189+263G>A rs7221604 66% Generates a new cryptic
splice donor site
0.563
Intron 15 c.2189+510T>G rs4889963 5% No effect on splicing 1.444
Intron 15 c.2189+607G>A rs112710614 7% No effect on splicing 0.189
Intron 15 c.2189+616T>C rs139307163 5% No effect on splicing 1.94
Intron 15 c.2189+723G>A rs4889819 20% No effect on splicing 0.367
Intron 15 c.2189+729A>G rs74737410 5% No effect on splicing 0.498
Intron 15 c.2189+859A>G rs4889964 5% No effect on splicing 1.503
Intron 15 c.2189+884G>A rs4889965 5% No effect on splicing 0.355
Intron 15 c.2189+1153A>G rs72850844 5% No effect on splicing 3.687
Intron 15 c.2189+1201C>A rs72850846 5% No effect on splicing 2.352
Intron 15 c.2189+1208A>G rs72850847 5% No effect on splicing 0.367
Intron 15 c.2189+1263A>G rs74700450 5% No effect on splicing 2.97
Intron 15 c.2189+1290A>G rs74003630 5% No effect on splicing 6.015
Intron 15 c.2189+1600C>T rs60668271 5% No effect on splicing 0.481
Intron 15 c.2190‐1531G>A rs74702528 0.9% (3% in African population) No effect on splicing 0.489
Intron 15 c.2190‐1463G>A rs116416508 0.9% (3% in African population) No effect on splicing 0.328
Intron 15 c.2190‐1139A>G rs184803352 0.7% (2% in African population No effect on splicing 0.095
Intron 15 c.2190‐1005A>G rs4889820 5% No effect on splicing 2.452
Intron 15 c.2190‐686G>A rs12452616 19% No effect on splicing 2.725
Intron 15 c.2190‐647G>A rs59362713 10% No effect on splicing 0.227
Intron 15 c.2190‐536G>A rs60429724 10% No effect on splicing 0.454
Intron 15 c.2190‐490G>A rs111477580 1% No effect on splicing 3.101
Intron 15 c.2190‐444A>G rs4889967 73% No effect on splicing 1.059
Intron 15 c.2190‐336C>T rs76178719 3% No effect on splicing 1.566
Intron 16 c.2331+20G>A rs2304832 75% No effect on splicing 5.346
Intron 16 c.2331+24T>C rs2304831 15% No effect on splicing 0.204
Intron 16 c.2331+151C>T rs111537160 2% No effect on splicing 0.608
Intron 16 c.2332‐198A>T rs2304830 73% No effect on splicing 3.363
Exon 17 c.2338G>A rs1126690 72% No effect on splicing 2.675
Exon 17 c.2446G>A rs1800314 5% No effect on splicing 5.793
Intron 17 c.2482‐132C>T rs113824706 0.9% (3% in African population) No effect on splicing 0.066
Exon 18 c.2553G>A rs1042397 57% Weakens a cryptic splice
donor site
1.241
Intron 18 c.2647‐71G>C rs4889821 5% No effect on splicing 3.473
Exon 19 c.2780C>T rs1800315 2% No effect on splicing 0.222
Intron 19 c.2800‐227C>G rs9890469 66% No effect on splicing 0.661
Intron 19 c.2800‐60G>A rs55662462 0.7% (11% in Latino population) No effect on splicing 2.209
Exon 20, 3ʹ UTR c.*3G>A rs1800317 5% No effect on splicing 0.03
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stronger enrichment in the catalytic core compared with the
mapping we performed previously (Niño et al., 2019; Figure 1c).
We included in the current version of the database common se-
quence variants that have a MAF≥1% and do not cause Pompe disease.
This resulted in a relative increase in the number of nondisease‐
associated variants (Table 2). We decided to include common sequence
variants in response to the misreporting of these variants as the principal
cause of disease in several patients. Examples of this are the c.547‐
67C>G (rs8069491) and 547‐39T>G (rs12452721) variants, which were
reported as the cause of disease while having an allele frequency of 67%
in the global population (Bekircan‐Kurt et al., 2017; Guevara‐Campos
et al., 2019). In total, the database now includes 148 variants with a
MAF≥1%. All variants had a low CADD score (<10; Table 2) and were
classified as “unknown.” We note that while these common sequence
TABLE 2 (Continued)







Exon 20, 3ʹ UTR c.*91G>A rs2229221 12% No effect on splicing 6.887
Exon 20, 3ʹ UTR c.*223C>T rs8132 22% No effect on splicing 3.025
Exon 20, 3ʹ UTR c.*419G>T rs7567 19% No effect on splicing 4.17
Abbreviations: CADD, Combined Annotation‐Dependent Depletion; mRNA, messenger RNA; UTR, untranslated region.
(a)
(b)
F IGURE 2 Expression study of seven disease‐associated missense variants in the GAA gene. (a) Overview of basic information regarding the
pathogenicity of selected variants. (b) Measured GAA activity in both cells and medium of COS‐7 cultures after transfection with the generated
constructs. Findings for the c.1597T>C variants are plotted separately as this was performed in a separate experiment. Data represent means,
error bars represent SD (n = 3 biological replicates), ***p < .001. CADD, Combined Annotation‐Dependent Depletion; mRNA, messenger RNA
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variants do not result in clinical manifestation of Pompe disease, it re-
mains possible that they might modify disease progression when present
in cis with a disease‐associated variant. In Pompe disease, this is the case
for the Asian pseudodeficiency allele (c.[1726G>A (p.Gly576-
Ser);2065G>A (p.Glu689Lys)]) and GAA2 (c.271G>A, (p.Asp91Asn)),
which have a MAF of 14% for c.1726G>A, 23.5% for c.2065G>A (both
East Asian), and 3.2% for GAA2 (European), and can be present in ciswith
known disease‐associated variants (Kroos et al., 2006; Labrousse
et al., 2010). Also, a variant with a low MAF in the general population,
c.510C>T (p.=) (rs564758226), is known to be linked to the late‐onset
variant c.−32‐13T>G (p.[=,0]) (IVS1). c.510C>T has a global MAF of
0.005%, but a MAF of 27.3% in compound heterozygous IVS1 patients
with symptom onset at childhood. It worsens aberrant splicing caused by
IVS1 and causes lower levels of leaky wild‐type splicing and lower GAA
enzyme activity, resulting in accelerated disease onset (Bergsma
et al., 2019).
Figure 2a,b shows the results on the GAA variants we subjected to
a more in‐depth investigation. We selected the common missense
variants c.307T>G (p.Cys103Gly), c.655G>A (p.Gly219Arg), c.670C>T
(p.Arg224Trp), c.1655T>C (p.Leu552Pro), and c.1798C>T (p.Arg600-
Cys) and performed in vitro analysis of their severity using SDM of GAA
cDNA expression constructs. In addition, c.1597T>C (p.Cys533Arg) and
c.309C>G (p.Cys103Trp) were tested due to a request for diagnostic
purposes. All of these variants fully abrogated GAA enzymatic activity
following transfection in COS‐7 cells (Figure 2, compare mutant GAA
with mock transfections). The c.309C>G variant was included because
the patient that harbored this variant in combination with c.525del
p.(Glu176Argfs*45) showed an atypical Pompe disease phenotype
(Mori et al., 2017). This case report described an adult patient with
cardiomyopathy. Molecular analysis of primary skin fibroblasts identi-
fied a reduction in GAA activity, although not at pathogenic levels, and
GAA activity was in the normal range for skeletal muscle tissue (Mori
et al., 2017). We note that the c.309C>G variant was not detected in
DNA from either parent and was described as a de novo variant (Mori
et al., 2017). This variant might have been introduced during embryonic
development, resulting in mosaicism similar to, as described previously
in Labrijn‐Marks et al. (2019) and in 't Groen et al. (2020). This might
explain the “uneven pattern” of glycogen accumulation in histological
sections derived from cardiac tissue (Mori et al., 2017). The in vitro
analysis indicated that the c.309C>G variant is fully deleterious and has
a predicted classic infantile phenotype in combination with a null allele.
A comprehensive genetic analysis would be necessary to confirm this
hypothesis.
Novel variants that have been reported only through NBS studies,
but for which no clinical phenotype has been provided, were classified as
“Unknown (found only in NBS)”. In the current version of the database,
26 variants have been classified as such (Table 3). Seven out of
26 variants were also present in cis with the Asian pseudodeficiency
allele, indicating that additional testing is required because the Asian
pseudodeficiency is known to result in false‐positive outcomes in dried
blood spot‐based assays (Liao et al., 2014; Momosaki et al., 2019). It is
currently unknown at what age symptoms will develop in neonates di-
agnosed with disease‐associated variants that are potentially associated
with a late‐onset phenotype. Symptoms might be delayed until late
adulthood or, for some genetic variants, might not even lead to disease.
In these cases, further research on the effect of the genetic variants is
essential to better inform patients, families, and doctors. As reported, in
these cases, the uncertainty of the diagnosis, the possibility of an
emerging disease, and the doubt on when to start treatment with ERT
could lead to emotional stress (Bodamer et al., 2017). This underscores
the importance of phenotype prediction for disease‐associated variants,
especially in the case of asymptomatic patients identified through NBS
programs.
The sharp increase in reports on patients with Pompe disease
and GAA disease‐associated variants highlights the need for regular
updates of the Pompe disease GAA variant database. Increased
awareness and improved diagnostic technology with exome and
genome sequencing and NBS programs are expected to further in-
crease the number of entries in the database in the coming years. It
will be important to link variants to clinical information and to test
their deleterious effect in vitro using expression and splicing assays.
Curated disease‐specific databases such as the Pompe disease GAA
variant database will be important to provide guidance to clinicians
and clinical geneticists to establish an accurate molecular diagnosis.
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